JP6100367B2 - Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物 - Google Patents

Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物 Download PDF

Info

Publication number
JP6100367B2
JP6100367B2 JP2015517190A JP2015517190A JP6100367B2 JP 6100367 B2 JP6100367 B2 JP 6100367B2 JP 2015517190 A JP2015517190 A JP 2015517190A JP 2015517190 A JP2015517190 A JP 2015517190A JP 6100367 B2 JP6100367 B2 JP 6100367B2
Authority
JP
Japan
Prior art keywords
slit3
osteoporosis
cells
protein
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015517190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527973A (ja
Inventor
ジュン‐ミン コ、
ジュン‐ミン コ、
ギ ス キム、
ギ ス キム、
スン フン リ、
スン フン リ、
ヨン‐サン リ、
ヨン‐サン リ、
ボム‐ジュン キム、
ボム‐ジュン キム、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asan Foundation
Original Assignee
Asan Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asan Foundation filed Critical Asan Foundation
Publication of JP2015527973A publication Critical patent/JP2015527973A/ja
Application granted granted Critical
Publication of JP6100367B2 publication Critical patent/JP6100367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
JP2015517190A 2012-06-15 2013-06-14 Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物 Active JP6100367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120064302 2012-06-15
KR10-2012-0064302 2012-06-15
PCT/KR2013/005282 WO2013187730A1 (ko) 2012-06-15 2013-06-14 Ｓｌｉｔ-Ｒｏｂｏ 시스템을 이용한 골절 또는 골다공증의 예방 또는 치료용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016177327A Division JP6216849B2 (ja) 2012-06-15 2016-09-12 Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物

Publications (2)

Publication Number Publication Date
JP2015527973A JP2015527973A (ja) 2015-09-24
JP6100367B2 true JP6100367B2 (ja) 2017-03-22

Family

ID=49758487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015517190A Active JP6100367B2 (ja) 2012-06-15 2013-06-14 Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物
JP2016177327A Active JP6216849B2 (ja) 2012-06-15 2016-09-12 Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016177327A Active JP6216849B2 (ja) 2012-06-15 2016-09-12 Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物

Country Status (6)

Country Link
US (1) US9802994B2 (enExample)
EP (2) EP3156074B1 (enExample)
JP (2) JP6100367B2 (enExample)
KR (2) KR101617497B1 (enExample)
CN (1) CN104582727B (enExample)
WO (1) WO2013187730A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3116521T3 (fi) 2014-03-14 2024-10-30 Univ New York State Res Found Luun kasvun ja luun rappeutumisen neurogeeninen regulaatio
KR101897322B1 (ko) * 2015-01-21 2018-09-10 재단법인 아산사회복지재단 원발성 갑상선암 전이의 진단방법 및 이를 이용한 진단키트
KR102011957B1 (ko) * 2016-06-08 2019-08-19 재단법인 아산사회복지재단 Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물
WO2017213435A1 (ko) * 2016-06-08 2017-12-14 재단법인 아산사회복지재단 Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물
JP7018458B2 (ja) 2017-06-02 2022-02-10 ファイザー・インク 組換えｒｏｂｏ２タンパク質、組成物、方法およびそれらの使用
WO2019161136A1 (en) * 2018-02-14 2019-08-22 Cornell University Slit and bone growth modulation
PH12021552079A1 (en) * 2019-02-27 2022-07-18 Daewoong Pharmaceutical Co Ltd Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
WO2024061158A1 (en) * 2022-09-20 2024-03-28 Everest Medicines (China) Co., Ltd. Slit2 related compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US20040265808A1 (en) * 2001-04-05 2004-12-30 Teresa Garcia Genes involved in osteogenesis, and methods of use
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
EP2212344B1 (en) * 2007-09-14 2014-03-26 Formycon AG Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP2036921A1 (en) * 2007-09-14 2009-03-18 Scil Technology GmbH Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP2621511A1 (en) * 2010-09-28 2013-08-07 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of bone density related diseases

Also Published As

Publication number Publication date
US20150175673A1 (en) 2015-06-25
KR101617497B1 (ko) 2016-05-03
KR20130141395A (ko) 2013-12-26
EP3156074A1 (en) 2017-04-19
JP2015527973A (ja) 2015-09-24
JP6216849B2 (ja) 2017-10-18
CN104582727B (zh) 2018-04-27
CN104582727A (zh) 2015-04-29
EP3156074B1 (en) 2019-06-05
EP2862580A4 (en) 2016-06-01
JP2017039729A (ja) 2017-02-23
WO2013187730A1 (ko) 2013-12-19
EP2862580A1 (en) 2015-04-22
US9802994B2 (en) 2017-10-31
KR20160032077A (ko) 2016-03-23

Similar Documents

Publication Publication Date Title
JP6216849B2 (ja) Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物
Prencipe et al. Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis
KR101508397B1 (ko) 염증성 장 질환의 검출 방법
KR20160138494A (ko) Fgfr 융합물
CN109310740B (zh) 使用slit－robo系统的预防或治疗肌肉减少症的组合物
JP7633338B2 (ja) 脳神経系疾患の治療または診断のための標的タンパク質としてのｐｃｎｔ
JP2022505327A (ja) Ｓｙｔ１１抑制剤を有効成分として含む胃癌治療用組成物
KR20150036102A (ko) 혈청 및 조직 생화학 마커로서 bag3
JP7604017B2 (ja) 動脈硬化重症度診断マーカーおよびこれを利用した診断方法
EP4400117A1 (en) Senolytic drug screening method and senolytic drug
US20130225656A1 (en) ANALYZING SEMAPHORIN7A (Sema7A) LEVELS FOR ASSESSING CANCER METASTATIC POTENTIAL AND METHODS OF TREATMENT
US8377436B2 (en) Granulysin and uses thereof
KR102678790B1 (ko) SARS-CoV-2 감염 질환 중증도 진단 또는 예후 예측용 바이오마커
CN111139299B (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
KR20180138021A (ko) 남성 생식기 질환 진단용 조성물, 남성 생식기 질환의 예방 또는 치료용 조성물, 및 이의 용도
KR20210061288A (ko) Cotl1을 유효성분으로 포함하는 인지기능장애 진단, 예방 또는 치료용 조성물
CN109414504B (zh) 药物组合物或食品组合物及评价活性成分体内效果的方法
KR102247913B1 (ko) 동맥경화 중증도 진단 마커 및 이를 이용한 진단 방법
CN114072504B (zh) 与癌干细胞特异性结合的适体及其用途
US20220403030A1 (en) Composition, comprising cotl1 as active ingredient, for diagnosis of bone disease or obesity
KR20170139461A (ko) 면역세포 수용체 2b4(cd244)의 염증성 장질환 진단 및 치료제로서의 용도
CN120700134A (zh) Tim-4在骨质疏松症诊治中的应用
KR20240040635A (ko) Cbfβ 발현 혈관평활근세포 또는 이의 배양액을 유효성분으로 포함하는 노인성 질환 예방 또는 치료용 약학 조성물
KR20240043697A (ko) 혈관석회화 치료제 스크리닝 방법
KR20130047874A (ko) 골 손실 진단 마커로서의 피브리노겐의 용도

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170222

R150 Certificate of patent or registration of utility model

Ref document number: 6100367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250